Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Clinical trial NCT06757387 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06757387
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-30
- Primary completion
- 2028-12-30
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.